ÐÔÊӽ紫ý

Las Vegas medical school study shows 35% increase in clinical trials since 2016.

Axsome Therapeutics’ Auvelity expanded its label to include treating agitation in Alzheimer’s disease patients. It’s just the second FDA-approved drug for this indication, and Axsome’s pill has a safety advantage.

Four years after gaining FDA approval for Auvelity to treat major depressive disorder (MDD), Axsome Therapeutics has tacked on a second nod in the United States for the first-in-class medicine to treat agitation associated with dementia caused by Alzheimer’s disease.

The agency’s decision marks the first approval of a drug with this specific mechanism of action for one of the most burdensome and clinically challenging symptoms of the disease.

Up to 76% of patients with Alzheimer’s disease experience agitation, including pacing, restlessness and verbal or physical aggression.

A new family of drugs works to rid Alzheimer’s Disease patients’ brains of the proteins believed to be behind the memory-robbing illness.

GLP-1s have been a breakthrough for obesity and diabetes. A 2022 study examined data from trials of GLP-1s in nearly 16,000 patients with diabetes, and showed that the drugs were associated with a 53% reduction in dementia risk.

More than 250 representatives are coming together to not only network but also share their dedication to find the cure for Alzheimer's. This includes announcing a new partnership with ÐÔÊӽ紫ý.